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Summary 
Bone marrow stromal cells promote B cell development involving recombinase gene-directed 
rearrangement of the immunoglobulin genes. We observed that the stromal cell-derived cy- 
tokine interleukin 7  (IL-7) enhances the expression of CD19 molecules on progenitor B-lin- 
eage cells in human bone marrow samples and downregulates the expression of terminal deoxy- 
nucleotidyl  transferase  (TdT)  and  the  recombinase-activating  genes  RAG-1  and  RAG-2. 
Initiation of the TdT downregulation on the first day of treatment, CD 19 upregulation during 
the second day, and RAG-1 and RAG-2 downmodulation during the third day implied a cas- 
cade of IL-7 effects. While CD19 ligation by divalent antibodies had no direct effect on TdT 
or RAG gene expression, CD19 cross-linkage complete blocked the IL-7 downregulation of 
RAG expression without affecting the earlier TdT response. These results suggest that signals 
generated through CD19  and the IL-7 receptor could modulate immunoglobulin gene rear- 
rangement and repertoire diversification during the early stages of B cell differentiation. 
T 
he commitment of hemopoietic stem cell progeny to 
the  B  lineage  and  the  progression  of differentiation 
along this pathway are dependent on environmental cues 
provided by specialized cells in hemopoietic tissues  (1-3). 
Stromal cells have been shown to mediate the development 
of B  cell precursors through intercellular contact and via 
the action of secreted factors (4,  5), including the stromal 
cell-derived cytokine IL-7 (6, 7).  The IL-7 receptors (IL- 
7R.), 1 a signal-transducing complex composed of Ix and Yc 
chains (8, 9), are expressed by pro-B and early pre-B cells 
(10,  11),  and IL-7 has been shown to induce proliferation 
of these B cell progenitors (7, 12, 13). The IL-7R is consti- 
tutively associated with the src family kinase p59@  n, and re- 
ceptor engagement  results  in  tyrosine phosphorylation of 
multiple substrates,  including phosphatidylinositol phospho- 
lipase  C  in some cell types (14-18).  Other soluble factors, 
such as stem cell factor (SCF), may potentiate the IL-7 pro- 
liferative effect (19, 20). 
B  lymphopoiesis in  the  mammalian  bone  marrow is  a 
complex process that involves an orderly rearrangement of 
Ig V(D)J  gene segments, whereby lymphocyte precursors 
*Abbreviations used in this paper: FBM, fetal  bone marrow; IL-7R_, IL-7 re- 
ceptor; P,T, reverse transcriptase; SCF, stem cell factor; slg, surface lg; 
TdT, terminal deoxynudeotidyl  transferase. 
are able to generate their enormous range of antigen bind- 
ing specificities (21).  P,.ecombinase enzymes are postulated 
to catalyze the Ig gene rearrangement process, which must 
be regulated to avoid productive V(D)J rearrangements on 
both chromosomes (22).  Although all of the recombinase 
components have yet to be defined, the expression of the 
recombinase-activating genes RAG-1  and lkAG-2  corre- 
lates well with recombinase activity (23), and disruption of 
either of these genes prevents the rearrangement of Ig and 
TCP, genes in mice  (24,  25).  The analysis  of RAG gene 
transcription  therefore  provides  a  convenient  index  of 
V(D)J  recombination  activity  and  its  regulation  during 
lymphoid development.  The  Ig  heavy chains  themselves 
have been implicated in the allelic  exclusion phenomenon 
(26-29) and cross-linkage of the Ig receptors on immature 
B  cells  aborts their development (30-32).  The signals  for 
recombinase machinery downregulation in early B-lineage 
cells, however, have not yet been identified. 
One of the earliest markers of B lineage differentiation is 
CD19,  a  transmembrane  glycoprotein  whose  expression 
begins in early B cell progenitors and increases with further 
differentiation until  it is  extinguished in  plasma  cells  (33, 
34). This 540-amino acid protein, possessing  a large "-,240 
amino  acid  cytoplasmic domain,  has  been implicated as a 
key signal  transduction molecule at several stages of B  cell 
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cascade of signaling events including calcium mobilization, 
activation  of phospholipase  C  and  protein  tyrosine  and 
serine kinases,  association with  PI 3-kinase,  and increased 
NFKB-binding  activity  (35-40).  Signal  transduction  via 
CD19  has been  examined extensively at the B  cell stage, 
where  the  net effect of these signaling events depends  on 
the nature and sequence of other transmembrane receptor 
signals  that  the  B  cell  receives.  For  example,  ligation  of 
CD19 on B  cells inhibits subsequent anti--surface Ig (slg)- 
induced  proliferation,  while  coligation  of CD19  and  slg 
decreases the activation threshold necessary for cell prolif- 
eration (35,  41-44).  Even before slgM is expressed, CD19 
may fimction as a signal transduction molecule in pro- and 
pre-B cells,  where it has been shown to be physically and 
functionally associated with src family kinases (45).  Among 
the phosphorylated substrates is CD19 itself (40,  46).  Inter- 
section  of the  CD19  pathway with  other  signaling path- 
ways is suggested by the finding that engagement of slgM, 
CD40,  or  CD72  also  induces  phosphorylation  of CD19 
(45,  46). 
In this  report,  we show that  treatment of human  bone 
marrow cells with rlL-7 results in a complex series of unan- 
ticipated effects: terminal deoxynucleotidyl transferase  (TdT) 
downregulation,  CD19  upregulation,  and  lastly,  RAG-1 
and ILAG-2 downregulation. The downregulatory effect of 
IL-7 on RAG-1  and RAG-2 expression could be reversed 
by CD19 antibodies, while CD19 ligation did not counter 
the negative IL-7 effect on TdT gene activity. These results 
suggest reciprocal involvement of the CD19 and IL-7E. in 
the fine tuning of early B cell differentiation and repertoire 
development. 
Materials  and Methods 
Cells.  Human bone marrow cells  were obtained  from 
aborted  fetuses in  accordance with  policies established  by 
an institutional review board. Mononuclear cells from fetal 
bone marrow (FBM) were isolated by centrifugation of cell 
suspensions  over  a  Ficoll-Hypaque  gradient  as  described 
previously (47). 
Antibodies.  mAbs used for cell surface analysis  included 
anti-CALLA, which recognizes CD10; anti-Leu-12, which 
recognizes the CD19 pan-B cell antigen; anti-Leu-6, which 
recognizes the more mature B  lineage antigen  CD20;  and 
anti-HPCA-2,  which  identifies the early stern cell marker 
CD34  (Becton  Dickinson  &  Co.,  Mountainview,  CA). 
Isotype control antibodies were also obtained from Becton 
Dickinson. Other mAbs included purified anti-CD19 from 
clone 25C1  (a generous gift from Dr. Stephen Pieper, Uni- 
versity of Louisville, Louisville, KY), anti-lL-71L antibod- 
ies from clone IL34-34 (a generous gift from Dr. Sam Sae- 
land,  Schering-Plough,  Dardilly,  France),  anti-human  tx 
chain,  SA-DA4-4  (48),  anti-human  surrogate light  chain, 
SLC2 (49),  and anti-human B29, CB3-2 (50).  Rabbit anti- 
TdT antibodies (Supertechs, Bethesda, MD) and goat anti- 
bodies to hlgM  (Southern  Biotechnology Associates,  Bir- 
mingham, AL) were used for intracellular staining. 
Short-term  Culture.  Mononuclear  FBM  cells  (l-2  X 
10~'/ml)  were  cultured  in  complete  ILPMI  1640  media 
(GIBCO BILL, Bethesda, MD) containing 5% heat-inacti- 
vated FCS (HI-FCS; Hyclone Laboratories, Logan, UT), 5  X 
10 -5 tool/liter 2-ME,  essential and nonessential amino ac- 
ids (Gibco), 2 retool/liter t-glutamine, MEM vitamins, and 
1% penicillin/streptomycin  (Gibco). rhIL-7 (100 ng/IL-7/ 
ml; PeproTech,  Inc., Rocky Hill, NJ) was added  to some 
cultures. 
Immunofluorescence Analysis.  For two-color surface anti- 
gen analysis,  viable cells were incubated with FITC-conju- 
gated CD34 for 15 min on ice, washed with PBS contain- 
ing 2% HI-FCS and 0.1%  azide,  and  counterstained  with 
PE-conjugated  mAbs specific for  CDI9.  For intracellular 
immunofluorescence  analysis,  cells  previously  stained  for 
surface  antigens  were  permeabilized  by  fixation  in  2% 
formaldehyde for 20 rain. Intracellular staining for Ix heavy 
chain and TdT was performed at room temperature in the 
presence of the  mild  detergent  0.5%  saponin  (Sigma  Im- 
munochemicals; St. Louis, MO). Isotype control antibodies 
were  used  to  stain  cells  to  deternfine  background  levels. 
Stained  cells  were washed and  then  analyzed by flow cy- 
tometry using a FACScan  |  instrument (Becton Dickinson). 
Cells were analyzed within  the lymphocyte gate that  was 
determined  by forward  light  scatter and  side  light  scatter 
properties. 
Isolation of Pro-B  Cells by Immunofluorescence Cell Sorting. 
From  the  FBM  population  of cells  stained  as  described 
above,  the  CD34+CD19 +  or  CD34+CD10 +  subpopula- 
tions  of lymphocytes  were  sorted  using  immunofluores- 
cence and light scatter characteristics with  a FACStar  ~' in- 
strument  (Becton  Dickinson).  Cell  purity  of >98%  was 
verified by reanalysis of the sorted cells. 
Analysis  of Gene  Expression.  CD34+CD19 +  cells  (0.3- 
2.3  ￿  10  s)  were  cultured  under  various  conditions  with 
medium alone, IL-7 (100 ng/nfl), and/or anti-CD19, anti-0,, 
anti-SLC,  and  anti-B29  antibodies.  The  antibodies  were 
used  at  a  concentration  of 10  ng/ml,  which  was  deter- 
mined by immunofluorescence assays of B lineage cell lines 
to  be  a  supersaturating  level  for the  relevant  cell  surface 
molecules.  Cells  were  then  collected,  counted,  and  total 
ILNA  was  extracted  using  Tri-Reagent  (Molecular  Re- 
search Center, Inc., Cincinnati, OH), a modification of the 
acid  phenol  technique  of Chomczynski  and  Sacchi  (51). 
Equal amounts ofiLNA were reverse-transcribed with I  ~M 
oligo(dT),  dNTPs  (5  raM),  20  U  of ILNAsin  (Promega, 
Madison, WI), and 5 U  of AMV reverse transcriptase (RT) 
in  a total buffer volume of 10  btl. PCR  amplification was 
performed using primers for [3-actin  (5'  GCG GGA AAT 
CGT GCG TGA CAT 3' and 5'  GTG GAC TTG (,GA 
GAG GAC TGG 3'), P,.AG-1  (5' TAC CTC CAG AA(; 
TTT ATG AAT 3'  and  5'  ATG ACA  GCA  GAT GA(" 
CTC CTA 3'), ILAG-2 (5' TTC TTG GCA TAC CAG 
GAG ACA  3' and 5' CTA TTT GCT TCT GCA CT(; 
AAA  3'),  TdT  (5'  ACA  CGA  AT(;  CAG  AAA  (;CA 
GGA 3' and 5' AGG CAA  CCT GAG CTT TTC AAA 
3'),  IgM (5' AAC  GGC AAC AAA  GAA AAG AAC  3' 
and 5' TGG TGG CAG CAA GTA GAC ATC 3'), rob-1 
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TCA  3'  and 5'  AGG GTA ACC  TCA  CTC  TTC  TCC 
AGG  CCA  GGC  3'),  B29  (5'  GAA  TCT  CTC  GCC 
ACC  CTC  ACC  3'  and 5'  CCT  TGC  TGT  CAT  CCT 
TGT  CCA  3'),  K (5'  TGG  CTG  CAC  CAT  CTG  TCT 
TCA  3'  and 5'  TTG  AAG CTC  TTT  GTG ACG  GGC 
3'),  or ~/  (5'  TCT  GTT  CCC  ACC  CTC  CTC  TGA 3' 
and  5'  TGG  TGG  TCT  CCA  CTC  CCG  CCT  3'). 
cDNA  samples  were  amplified for  30  cycles for  RAG-1 
and RAG-2  at an annealing temperature of 55~  or for 30 
cycles for [3-actin and the others at an annealing tempera- 
ture  of 60~  For each  cDNA preparation, a  control syn- 
thesis reaction was  performed without  RT  to  ensure  that 
there  was  no  contaminating genomic  DNA.  PCR  condi- 
tions were optimized so that 30 cycles was in the exponen- 
tial phase  of the  amplification. The  samples were  electro- 
phoresed  on  a  1%  agarose  gel  and  blotted  onto  Nytran 
membranes  (Schleicher &  Schuell, Inc., Keene, NH).  The 
membranes  were  prehybridized (1  M  NaC1,  0.2  M  Tris, 
pH  7.5,  0.1%  SDS,  and 200  txg/ml salmon sperm DNA), 
then hybridized using internal probes for [3-actin (5'  CCG 
GCC  CCT  CCA  TCG  TCC  AC  3'),  RAG-1  (5'  CCA 
TTA  GGC  ATA GAG GAC 3'), RAG-2  (5'  GAG TCT 
TCA  AAG GGA GTG  G  3'), TdT  (5'  AAC AGA GGA 
TGA  AGA  GCA  3'),  IgM  (5'  CTA  CAA  GGT  GAC 
CAG  CAC  ACT  3'),  mb-1  (5'  TGT  CCC  ACT  CTT 
CTT  CCC  TCT  3'),  B29  (5'  CGTG  TTT  GAG  GAC 
A_AT GGC  ATC  3'),  ~  (5'  CAT  CTT  CCC  GCC  ATC 
TGA  TGA  3'),  or  ~/  (5'  GCC  ACA  CTG  GTG  TGT 
CTC  ATA  3')  that  had  been  end  labeled with  32p.  The 
blots were washed in 1￿  SSC +  0.1% SDS, scanned with a 
phosphorimager  (Molecular  Dynamics  Inc.,  Sunnyvale, 
CA) to quantify signal intensity, and exposed to x-ray film. 
To  obtain  a  semiquantitative  estimate  of gene  expression 
levels, signal intensity of the B  lineage genes was  normal- 
ized to the [3-actin signal. 
Cell  Viability.  Cellular viability was  estimated over the 
culture interval by trypan blue exclusion and by propidium 
iodide uptake. Cells were incubated with  1.0  Ixg/ml PI in 
PBS  +  2% HI-FCS for 5 min on ice, and propidium iodide 
uptake was analyzed by automated flow cytometry using a 
FACScan  ~  instrument.  The  two  methods  of cell viability 
analysis yielded comparable results. 
Results 
The  Effect  of IL-7  on  FBM Mononuclear  Cells.  Human 
mononuclear  FBM  cells  cultured  in  the  presence  or  ab- 
sence  of  IL-7  (100  ng/ml)  were  collected  after  3  d, 
counted,  and  analyzed  for  the  B  lineage  markers  CD34, 
CD19,  CD10,  CD20,  CD24,  CD45,  and slgM. The  IL-7 
treatment resulted in an increase in the cell surface expres- 
sion  of the  CD19  pan-B  cell marker,  as noted  previously 
by Wolf and  co-workers  (52).  The  pro-B  cell population 
appeared to be the most responsive to IL-7, as indicated by 
a  three-  to  fourfold increase in  the  mean  fluorescence in- 
tensity of CD19  on the  CD34 +  subpopulation  (Fig.  1 A). 
IL-7  also  induced  a  twofold  increase  in  the  relative fre- 
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Figure 1.  (A) Effect oflL-7 treatment on B lineage cells  in FBM. Anal- 
ysis of mononuclear FBM cells expressing both CD34  and CD19  after 
culturing in medium alone or 100 ng/ml IL-7 for 3 d. Data is represented 
by the  percentage of expressing cells within  the  lymphocyte gate. (/3) 
Time course oflL-7 treatment on CD19 expression of FBM cells. CD19 
expression  by mononuclear FBM cells  treated with 100 ng/ml IL-7 for 5 d 
at daily intervals was analyzed. CD19  expression was measured by the 
mean fluorescence index with  the  medium  control  mean fluorescence 
value equal to 1 and the IL-7 value being relative to that value. (C) Effect 
of other growth factors on CD 19 expression in FBM. Analysis  of CD19 
expression by mononuclear FBM cells treated with medium alone, 100 
ng/ml IL-7, 100 U/ml IL-3, 20 ng/ml TGF-13, 10 ng/ml SCF for 3 d in 
three experiments. CD 19 expression was measured by mean fluorescence 
index as described above. A significant increase in CD19 expression was 
induced by IL-7 (P <0.005), whereas the other cytokines had no demon- 
strable effect (P >0.10). 
quency  of CD20 +  ceils  (mean  of 56.2  +  6.4%  SE versus 
28.5  +  6.4% control values; Student's t test, P  <  0.005)  in 
keeping with  the  results  of Saeland  and  co-workers  (12). 
The  frequency  of CD34 +  lymphocytes,  which  also  ex- 
pressed CD20,  increased from  3  to  6%  after  culture with 
IL-7. The  IL-7 treatment had no  effect on  the  expression 
of other  cell surface  markers  of B  lineage cells, including 
IgM, CD10,  CD24,  and CD45  (data not shown). A time course analysis of the effect oflL-7 on CD19 ex- 
pression revealed that the IL-7-induced increase in cell sur- 
face expression of CD19 was initiated between 1 and 2  d, 
and the maximal effect occurred by day 3  (Fig. 1 B). Other 
growth factors, including the SCF, IL-3, and TGFq3, had 
no effect on CD19 expression (Fig. 1 C). These results sug- 
gest that the specific effects of IL-7 on early B lineage cells 
in humans include a  pronounced enhancement of CD19 
expression, which is  a  normal feature  of their differentia- 
tion. 
Effect of IL-7 Treatment on tntraceltular Proteins.  The en- 
zyme TdT is expressed in the nucleus of the progenitors of 
B and T  cells (53-55), where it catalyzes the random incor- 
poration  of nonencoded nucleotides  (N  residues)  during 
the rearrangement oflg and TCR  (56-58). When we used 
intracellular immunofluorescence to evaluate TdT expres- 
sion by FBM cells,  IL-7 treatment was found to  decrease 
TdT levels by ,'~  in the pro-B subpopulation of cells 
(Fig. 2). 
Because  the  intracellular expression  of p~  heavy  chains 
can be  used to  characterize the  pre-B  cell stage  (59),  we 
also examined the IL-7 effect on ~  chain expression. The 
outcome of these experiments revealed that the frequency 
of bone marrow lymphocytes expressing b~ heavy chains in 
their cytoplasm was unaffected by IL-7 treatment (control: 
47  +  6% versus IL-7:45 +  9%), thus reinforcing the idea 
that IL-7 acts primarily on pro-B cells. 
IL-7 Effects on  Gene Expression  by  Pro-B  Cells.  To  ex- 
plore  further  their  response  to  IL-7,  the  CD34+CD19 + 
population of pro-B  cells was  isolated and the  cells were 
cultured for 3  d with and without rlL-7. IL-7 did not en- 
hance the growth of the pro-B population; 95  -  4% of the 
initial input was recovered after 3 d in control cultures ver- 
sus 96 +  3% for the IL-7-treated cultures. In addition, cell 
viability was  not  significantly altered  by  IL-7  treatment 
during the 3-d culture interval; 93 +  4% of the IL-7-treated 
cells were viable after 3 d versus 92 +  3% of the nontreated 
cells.  Since only limited numbers of CD34+CD19 +  cells 
were available (0.3-2.3 ￿  10  s in a typical experiment), the 
effect of IL-7 on pro-B cell gene expression was measured 
by RT-PCR.  In keeping with  the  protein analysis, TdT 
message levels were downregulated by IL-7 (Fig. 3 A). The 
IL-7-induced  TdT  +  inhibition  was  striking  but  never 
complete.  A  mean of 65%  inhibition (--- 17%  SE;  P  < 
0.005) of the TdT transcript levels (normalized to [3-actin) 
was observed in 10 experiments. Of the other genes exam- 
ined, the most remarkable effect of IL-7 was a decrease in 
the  levels of RAG-1  and RAG-2 ml<NA to  "-,25%  and 
48% of the respective control values (Fig. 3, A  and/3). In 
view  of this  RAG-1  and  RAG-2  downmodulation, the 
progression of heavy chain gene rearrangement to generate 
p~+ pre-B cells would not be anticipated, and the lack of an 
Figure 2.  TdT downregulation by IL-7 treatment. Sorted CD34  +- 
CD19  + FBM cells were placed into culture for 3 d in the presence and 
absence of 100 ng/ml IL-7. The cells were then permeabilized  by formal- 
dehyde fixation,  stained  with anti-TdT antibody,  and analyzed  by FACS  | 
for intracellular  TdT expression. The data were derived from three sepa- 
rate experiments. 
Figure 3.  (A) IL-7 downregulates  RAG-l/2 and TdT gene expression 
in CD34+CD19  + FBM cells, and anti-IL-7R antibody negates these ef- 
fects. CD34+CD19  + cells were placed into culture for 3 d with medium 
alone, 100 ng/nd IL-7, or IL-7 +  anti-IL-7P,.. (B) IL-7 treatment does 
not  affect expression of lgM, rob-l,  B29, K,  and  k  genes. Sorted 
CD34+CD19  + FBM cells were placed into culture with medium alone or 
100 ng/ml 1L-7 for 3 d. The index of expression was derived from the 
measurement of band intensity normalized  to the [3-actin  band intensity. 
The data shown were derived from four identical experiments in which 
pro-B cells were isolated from different FBM samples. Only the RAG-1 
and RAG-2 values  were significantly  affected (P <0,005, Student's t test). 
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firmed by immunofluorescence analysis after permeabiliza- 
tion of the isolated pro-B cells. The addition of an antago- 
nistic  anti-IL-7R  antibody  (60)  to  the  IL-7-treated 
cultures  blocked  the  downregulation of RAG  and  TdT 
mRNA levels, thus confirming the involvement of the IL- 
7R in mediating the IL-7 effects (Fig. 3 A). IL-7 treatment 
did  not  alter  transcript levels  for  bL  heavy  chains,  mb-1 
(Iger  B29 (Ig[3), and K or k light chains (Fig. 3 B), suggest- 
ing that the effects of this cytokine on pro-B cells are rela- 
tively specific. 
As an initial approach to determining the mechanism(s) 
of the IL-7 effects, the kinetics of the suppression of RAG-l, 
RAG-2,  and  TdT  gene  expression  were  examined. 
CD34+CD19 +  pro-B  cells  were  cultured  as  before  and 
harvested  daily for  analysis. The  downregulation of TdT 
gene expression occurred during the  1st  d  (Fig. 4).  Addi- 
tional studies revealed that  the  TdT  downregulation oc- 
curred  within  the  first  6  h  of IL-7  treatment  (data  not 
shown). In contrast, the downregulation of RAG-1 (Fig. 4) 
and RAG-2 gene  expression  (not  shown)  did  not  occur 
until after the second day of IL-7 treatment, thus implying 
that  a  cascade  of effects  is  initiated via the  IL-7R on the 
pro-B cells. 
Anti-CD19  Counteracts  the  IL-7-induced  RAG-1  and 
RAG-2  Downregulation,  but  not  the  Effect  on  TdT  Gene 
Expression.  Because the downregulatory effect of IL-7 on 
RAG-1 and RAG-2 gene expression followed the increase 
in cell surface expression of CD19, we examined the effect 
of anti-CD19  antibodies on  the  outcome  of IL-7  treat- 
ment. Ligation of the CD19 molecules on the pro-B cells 
by treatment with anti-CD19 antibodies completely abro- 
gated  the  downregulatory effects  of IL-7  on RAG-1  and 
RAG-2 gene expression, but had  no  effect  on the  IL-7- 
mediated downregulation of TdT expression (Fig. 5). We 
also used the CD10 antibody instead of anti-CD19 to iso- 
late CD34 + pro-B cells to ensure that the CD19 antibody 
r  1,  .o_ 
0.6 
"0 
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Figure 4.  Time course analysis  of the IL-7 effects on RAG-1 and TdT 
gene expression by pro-B cells. Sorted CD34+CD19  + FBM cells were 
placed into culture with medium alone or 100 ng/ml IL-7. Cells were 
collected daily for 3 d. PCK products measured by phosphorimage scan- 
ning and the index of expression was calculated  as described in Fig. 3. 
Figure 5.  The effect ofCD19 ligation  on RAG-l/2 and TdT gene ex- 
pression. Sorted CD34+CD10  + FBM cells were placed into culture with 
medium alone, 100 ng/ml IL-7, 10 ng/ml anti-CD19, or IL-7 and anti- 
CD19. The data obtained by phosphorimage scanning were normalized 
to J3-actin expression as described in Fig. 3. The data from five experi- 
ments indicate that the downregulation of RAG-l, RAG-2, and TdT 
gene expression  by IL-7 was statistically  significant  for each of these genes 
(Student's t test, P < 0.005). The values  for these genes found when anti- 
CD19 was added together with IL-7 were also significantly  different  from 
those found with IL-7 alone (P < 0.005). 
Figure  6.  RAG-1 expression  in IL-7-treated pro-B cells is unaffected 
by treatment with anti-BCR antibodies.  CD34+CD19  + cells  were placed 
into culture with medium alone, 10 ng/ml anti-lgM, 10 ng/ml anti-SLC, 
or 10 ng/ml anti-B29 in the presence and absence of IL-7. The data ob- 
tained from three experiments  were derived by phosphorimage scanning. 
The data showed that these antibodies  had no demonstrable  effect (P > 
0.10) on RAG-1 values. 
staining was not responsible for the downregulatory effect. 
The results in these experiments were the same, regardless 
of whether the CD19 or CD10 antibodies were used with 
the CD34 antibody for the isolation of pro-B cells. In con- 
trast to the anti-CD19 effect, incubation of the pro-B cell 
population with  antibodies to  p~  heavy  chains,  surrogate 
light chains, and the Ig[3 chains, which are  essential com- 
ponents of both pre-B and B  cell receptors,  had no effect 
on expression of the recombinatory genes, RAG-l, RAG-2, 
or TdT either in the presence or absence of IL-7  (Fig.  6 
and data not shown). 
Discussion 
This study provides evidence for a novel regulatory po- 
tential of two key circuits in the interaction between stro- 
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marrow, namely (a) the stromal cell-derived cytokine IL-7 
arid its complementary IL-71K on pro- and pre-B cells; and 
(b)  the  signal-transducing  CD19  molecule  on  B  lineage 
cells  and its postulated ligand on stromal cells.  The results 
indicate that while the first of these circuits (IL-7-~IL-71K) 
may enhance the second by upregulating CD19 expression, 
the  two  types of interactions  exert antagonistic effects on 
expression of genes intimately involved in the assembly of 
Ig variable region genes. 
IL-7 serves as  an  essential  growth  factor for B  lineage 
precursors in mice via its interaction with the signal-trans- 
ducing  1L-7R  complex  (IL-71Kcl2tc) that  is  expressed  on 
pro- and pre-B cells  (11).  Treatment of mice with  either 
anti-IL-7 or anti-IL-71L0~  antibodies blocks the  early de- 
velopment of B lineage cells in the bone marrow (11,  61), 
and a similar developmental block is seen in gene-targeted 
mice whose  IL-7Yc  gene is disrupted  (62).  By contrast,  in 
humans,  an essential growth-promoting role for the IL-7/ 
IL-7R interaction is not well established for B lineage pre- 
cursors.  Only a  modest  IL-7 proliferative effect could  be 
demonstrated for human bone marrow precursors by Sae- 
land and coworkers (12) and in the present studies. Our re- 
sults  confirm an approximately twofold increase in the fre- 
quency of cells that express CD20, but fail to show growth 
of  the  pro-B  cell  population.  The  existence  of  other 
growth-promoting factors for human  B  cell  precursors  is 
implied by the development of normal numbers of B  cells 
in boys who have X-linked severe combined immunodefi- 
ciency because of a function loss mutation in their IL-7 Yc 
gene (63).  These observations indicate the existence of sig- 
nificant differences in the biological roles for IL-7 and IL- 
71K, in B lineage cells of mice and humans. 
IL-7 treatment has been reported to sustain expression of 
the RAG-1 and RAG-2 genes and to enhance V(D)J[3 re- 
arrangement by murine pre-T cells (64). Those studies used 
an intact thymic organ culture system, where it was impos- 
sible to determine whether the IL-7 effects were direct or 
indirect.  Other murine studies have shown that pre-B cell 
lines  established from EbL-bcl2  transgenic  mice proliferate 
in the presence of stromal ceils  and IL-7, but the removal 
of lL-7 results in transient upregulation of 1LAG-l/2 gene 
expression followed by a  decrease  in  expression  with  the 
progression of differentiation into IgM-bearing B cells (65). 
This  suggests  that  IL-7  may  have  a  biphasic  effect  on 
RAG-l/2  expression.  These results in mice raise interest- 
ing questions about potential differences between IL-7 ef- 
fects on early T  and B lineage cells. 
The present data suggest that  IL-7 promotes the differ- 
entiation of human B progenitors. In keeping with the ob- 
servations of Wolf and co-workers (52),  IL-7 treatment en- 
hanced  the  level  of  CD19  expression  by  the  CD34  + 
population ofpro-B cells. A similar effect was noted for the 
CD34-  population  of pre-B  cells,  although  the  natural 
level of CD 19 expression is already higher by this differen- 
tiation  stage.  More  compelling evidence for a  differentia- 
tion  promoting effect of the  IL-7/IL-7R interaction  was 
observed in our analysis of B-lineage--specific gene activity. 
IL-7 treatment resulted in diminished expression of the re- 
combinase genes RAG-1  and  RAG-2,  as well as  a  rapid 
downregulation of TdT gene transcripts. Since the analysis 
of RAG-1  and RAG-2 gene expression provides an indi- 
rect measure of V(D)J rearrangement,  and TdT activity is 
essential  for  N  sequence  diversification  of CDR3  V(D)J 
joins, this suggests that IL-7 could play an important role in 
regulating repertoire development during B lymphopoiesis. 
This  interpretation  is  reinforced  by the  specificity of the 
IL-7 effect in that the expression of genes encoding the Ig 
receptor  components  IgH,  IgL,  Ig{x, and  Ig[3 was  totally 
unaffected by IL-7 treatment. Moreover, the downregula- 
tory effects of the IL-7 treatment on the TdT, RAG-l, and 
RAG-2 genes were abrogated by an anti-IL-7R antibody 
with proven antagonist characteristics (60). 
The temporal relationship of these IL-7 effects suggests a 
cascade  phenomenon.  While  downmodulation  of  TdT 
gene expression occurred within the first 6 h of IL-7 treat- 
ment,  downregulation  of RAG-1  and  RAG-2  gene  ex- 
pression was not observed until  the 3rd day of treatment. 
The upregulatory effect on CD19 expression began during 
the  2nd  d  of IL-7 treatment,  and  the  maximal effect was 
not seen until the 3rd d of treatment. This temporal associ- 
ation between an increase in CD19 expression and the de- 
crease in RAG gene expression raised the possibility that a 
signal generated via the CD19 molecule itself might be re- 
sponsible  for  silencing  RAG  expression.  Wolf  and  co- 
workers (52), who previously noted the upregulatory effect 
on IL-7 on CD19  expression, demonstrated an increase in 
homotypic  interaction  between  the  CD19  molecules  on 
precursor cells. A  CD19 ligand could also be expressed by 
stromal  cells,  although  we  are  unaware  of published  data 
supporting this hypothesis.  On testing the effect of CD19 
ligation,  we  made  the  surprising  observation  that  CD19 
cross-linkage by antibodies  completely negates the  down- 
regulatory  effect of IL-7  on  RAG-l/2  expression,  while 
having no demonstrable effect on its own. This remarkable 
antagonistic effect of CD 19 ligation appears relatively spe- 
cific in that the IL-7 downmodulation  of TdT expression, 
which occurs earlier, was completely unaffected. 
A large body of evidence indicates that heavy chain ex- 
pression, perhaps together with surrogate light  chains,  re- 
sults  in  a negative signal for VDJH rearrangement  (2l,  29, 
66, 67), but our results suggest that the stromal cell/precur- 
sor cell  interactions  involving cytokine  and  other  non-Ig 
cell surface receptors on the B lineage precursors could also 
influence Ig assembly by modulating the activity of the re- 
combinase genes. To test the alternative possibility that IL-7 
treatment might induce  expression of an Ig or Ig-like re- 
ceptor, which in turn could transduce a negative signal for 
recombinase gene activity perhaps via CD19, we examined 
the effects of a variety of antireceptor antibodies.  None of 
these  antibodies  against pre-B  or B  cell receptor compo- 
nents, which included anti-~HC, anti-t[JLC, and anti-Ig[3, 
had a demonstrable effect on recombinase gene activity of 
pro-B  cells  cultured  either in  the  presence  or absence of 
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downregulation  of recombinase gene activity is not medi- 
ated indirectly via Ig or Ig-like receptors. 
The in vitro demonstration of antagonistic effects of IL- 
7R  and  CD19  ligation  on  Ig gene  recombinase  activity 
raises  the  question  of physiological relevance.  Our results 
can be considered within the context of a stepwise differ- 
entiation model based on observations indicating that B cell 
precursors are initially dependent  on stromal cell contact, 
then on stromal cells plus IL-7, and finally IL-7 alone as the 
precursor cells progressively differentiate to become imma- 
ture surface Ig-expressing B cells (3, 68). The idea of an in- 
tersection between the CD19- and  IL-7R-signating path- 
ways is favored by the observation of the phosphorylation 
of an unidentified  85-95-kD  protein after IL-7R engage- 
ment (14,  15); moreover, IL-7 may also induce phosphory- 
lation of CD19  in precursor B  cells  (45).  This type of re- 
ceptor "cross-talk" is not unique to the IL-7R; aggregation 
of slg,  CD40,  and  CD72  also  phosphorylates  CD19  (45, 
46).  Previous observations suggest that pro-B cells may in- 
teract with stromal cells, possibly via CD19 binding with a 
stromal cell ligand,  to enhance IL-7 production  (3,  5,  69), 
and our data indicate that IL-7 could then interact with IL-7R 
on pro-B cells  to initiate  downregulation  of TdT expres- 
sion and the upregulation of CD19 expression. The RAG-1 
and RAG-2 genes would  continue to be expressed in the 
presence of IL-7 for as long as the CD19 ligation persists. 
As  the  precursor  cells  respond with  an  increase  in  CD19 
expression and  undergo  further maturation to  the stromal 
cell  contact-independent  stage,  however,  they  may  be 
physically displaced  from stromal  cell  contact  as  a  conse- 
quence  of population expansion.  In the absence of CD19 
ligation,  IL-7/IL-7R-mediated signals  would  then initiate 
the process of RAG gene downregulation.  The phosphor- 
ylation of a critical threonine residue in RAG-2 by cell di- 
vision control kinases has been shown  to result in a rapid 
degradation of the protein (70),  indicating that the regula- 
tion of recombinase activity may be fine tuned further by 
posttranslational  events.  Later,  when  the  pre-B  cells  and 
newly formed B cells begin to express their receptors, ~, K, 
or XLC/IxHC/Ig0t[3, these may interact with their ligands 
to terminate recombinase gene activity (32). 
Our data suggest that CD19  and IL-7 may serve as im- 
portant  coregnlators of early B  lymphocyte differentiation 
during which pro-B cells progress through the next devel- 
opmental stage of pre-B cells.  One prediction of these re- 
sults  is  that  loss  of CD19  function  would  interfere  with 
early  B  cell  development  unless  compensatory  signaling 
pathways exist. CD19 deficiency has not been reported yet, 
but transgenic mice that overexpress hCD19  display a sig- 
nificant block in B  lymphocyte development at the pre-B 
cell  stage, the severity of which correlates with the level of 
hCD19  expression in  different transgenic  lines  (71).  This 
suggests the human protein may behave as a dominant neg- 
ative mutant in  the mouse.  The phenotype of these mice 
could  reflect  premature  downregulation  of RAG-1  and 
KAG-2 gene activity in pre-B cells  in which  the  IL-7R- 
negative signal is not counteracted by CD19 ligation. Un- 
der  these  circumstances,  light  chain  gene  rearrangement 
and B cell development would be impaired. 
The  downregulatory  effect of IL-7 on  TdT  expression 
by pro-B  cells  is  an  unprecedented  observation  that  de- 
serves  special  comment.  This  effect  occurred  within  the 
first 6 h of IL-7 treatment of the pro-B cells and, in further 
contrast to the RAG1/2 downregulation,  could not be re- 
versed by CD19 ligation. Although unnecessary for V(D)J 
recombination, TdT is responsible for the insertion of non- 
encoded nucleotides in the V(D)J splice sites,  and these N 
sequences make a major contribution to antibody diversity 
(21,  56).  While N  sequences are characteristically found in 
VDJH  splices of all heavy chain genes expressed by B  cells 
generated beyond the embryonic phase  (72,  73),  they are 
not found in most light chain VJ joins  (74,  75).  This im- 
plies the cessation of TdT activity before most of the light 
chain  genes  are  rearranged.  TdT  downregulation  via the 
IL-7  ----) IL-7R interaction  suggests  a  mechanism  for the 
initiation  of TdT  gene  silencing  before  the  recombinase 
genes RAG-1 and RAG-2, which are needed for comple- 
tion of the LC gene rearrangement process, and B cell for- 
mation. 
The complex signal transduction  pathways which  must 
exist to mediate the antagonistic effects of IL-7 and CD19 
ligation on Ig gene recombinase represent fascinating issues 
for study. One clue to this puzzle may be provided by the 
analysis  of pro-B cells  from patients with X-linked agam- 
maglobulinemia.  Function-loss  mutations  in  the  cytoplas- 
mic  tyrosine  kinase,  Bruton's  tyrosine  kinase,  result  in 
faulty pro-B/pre-B ceU differentiation and pan-hypogam- 
maglobulinemia due to the resultant B-cell deficiency (76, 
77).  Abnormal carryover of TdT expression into the pre-B 
cell phase has been observed in XLA patients (78,  79)  and, 
when the effect of IL-7 was examined, we noted that IL-7 
did not induce  TdT downregulation  in XLA pro-B cells, 
but it still induced RAG-1  and RAG-2 downmodulation. 
Remarkably, the ligation of CD19 molecules on XLA pro-B 
cells  did not  negate the negative IL-7 effect on recombi- 
nase  gene  activity  (Billips,  L.G.,  N.  Nishimoto,  C.A., 
Nufiez,  P.D.  Burrows,  M.D.  Cooper,  and H.  Kubagawa, 
manuscript  in  preparation).  These  results  implicate  Bru- 
ton's tyrosine kinase as an essential participant in the IL-7R 
and CD19  signal transduction  pathways that modulate re- 
combinase gene activity. 
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